Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy

British Journal of Dermatology

Volumn 152, Issue 6, 2005, Pages 1199-1205

  Brennand, S ^a   Sutton, V R ^b   Biagi, J ^a   Trapani, J A ^b   Westerman, D ^a   McCormack, C J ^a   Seymour, J F ^a   Kennedy, G ^a   Prince, H Miles ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Apoptosis; Bexarotene; Cutaneous T cell lymphoma; S zary cells

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; CASPASE 3; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; CHLORMETHINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DENILEUKIN DIFTITOX; DNA FRAGMENT; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREDNISOLONE; PROPIDIUM IODIDE; RETINOID X RECEPTOR; STAUROSPORINE; STEROID; TRYPAN BLUE; UNINDEXED DRUG; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MECHANISM; ELECTRON BEAM; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NICK END LABELING; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PUVA; SEZARY CELL; SEZARY SYNDROME; SKIN BIOPSY; ULTRAVIOLET B RADIATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICARCINOGENIC AGENTS; APOPTOSIS; FEMALE; HUMANS; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; SEZARY SYNDROME; SKIN NEOPLASMS; STAINING AND LABELING; TETRAHYDRONAPHTHALENES; TUMOR CELLS, CULTURED;

EID: 21644469232     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06539.x     Document Type: Article

References (21)

1. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sézary syndrome. Blood 1996; 88:2385-409.
2. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-57.
3. Zhang C, Kamarashev J, Qin J et al. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol 2003; 200:249-54.
4. Nevala H, Karenko L, Väkevä L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol 2001; 145:928-37.
5. Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol 1999; 107:707-11.
6. Osella-Abate S, Zaccagna A, Savoia P et al. Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy. J Am Acad Dermatol 2001; 44:40-7.
7. Miller VA, Benedetti FM, Rigas JR et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15:790-5.
8. Nagy L, Thomázy VA, Shipley GL et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995; 15:3540-51.
9. Kizaki M, Dawson MI, Heyman R et al. Effects of novel retinoid X receptor-selective ligands on myeloid leukemic differentiation and proliferation in vitro. Blood 1996; 87:1977-84.
10. Gamage SD, Bischoff ED, Burroughs KD et al. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma. J Pharmacol Exp Ther 2000; 295:677-81.
11. Song JI, Lango MN, Hwang JD et al. Abrogation of transforming growth factor-α/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res 2001; 61:5919-25.
12. Darro F, Cahen P, Vianna A et al. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Breast Cancer Res Treat 1998; 51:39-55.
13. Zhang C, Hazarika P, Ni X et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002; 8:1234-40.
14. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19:2456-71.
15. Prince HM, McCormack C, Ryan G et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Aust J Dermatol 2001; 42:91-7.
16. Cheng S, Kupper T. A new rexinoid for cutaneous T-cell lymphoma. Arch Dermatol 2001; 137:649-52.
17. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83:841-50.
18. Nawa T, Nawa MT, Cai T et al. Repression of TNF-α-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun 2000; 275:406-11.
19. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995; 131:1003-8.
20. Diamandidou E, Colome M, Fayad L et al. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 1999; 40:914-24.
21. Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137:581-93.